6 Apr 2022 , 01:34 PM
As per the regualtory filing, the present manufacturing facility of target entity i.e., Casper Pharma Private Limited has installed capacity of 1.2 Bn tablets/ capsules. The company is ready for USFDA inspection which is expected to happen within next 6 months’ timeframe.
The Unit is yet to reach its commercially viable operations. As such the turnover details are not available to disclose.
The acquisition consideration will be USD 20.50 million based on the present exchange rate equivalent to around Rs155 crore will be paid to the sellers of the shares in target entity.
At around 1:30 PM, Suven Pharmaceuticals was trading at Rs607.30 per piece lower by 0.78% on Sensex.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.